力尔凡+DF方案治疗多发性转移食管癌的临床观察  

Clinical Study of Multiple Metastatic Esophageal Carcinoma Treated with LIFEIN and DF

作　　者：石永刚[1] 韩鑫[1] 田爱玲[1] 马桂玲[1] 祁超[1] 

机构地区：[1]河南医科大学第一附属医院放疗科,郑州市450052

出　　处：《中国肿瘤临床》2001年第6期441-442,449,共3页Chinese Journal of Clinical Oncology

摘　　要：目的：研究力尔凡提高晚期食管癌化疗的疗效及减轻化疗反应的作用。方法：72例伴有远处转移的晚期食管癌患者随机分为治疗组（37例）和对照组（35例），治疗组采用力尔凡＋DF方案，对照组单用DF方案。力尔凡给药方案：第1～3天皮下注射，5mg／天；第4～8天改为静点，5mg／天；第9～28天静点，10mg／天。28天为一疗程。治疗组在采用DF方案第1、3疗程的同时应用力尔凡。DF方案 DDP 100mg／m2，分2～3天；5－FU 500mg／m2，1～5天。21天一疗程，连用4个疗程。结果：治疗组全部按计划完成治疗，对照组有4例未完成。近期疗效：治疗组有效率为62％，对照组为32％（χ2＝6．166 6 P＜0．05）。治疗组中位生存时间为10个月，对照组为6个月。副作用：治疗组呕吐反应和腹泻的发生率及外周血白细胞和血小板下降的幅度均明显低于对照组，而发热和皮疹的发生率则高于对照组。治疗组治疗后T细胞亚群中的CD3，CD4，CD4／CD8有明显提高，而对照组治疗前后无明显变化。结论：力尔凡能够有效地提高晚期食管癌的化疗效果，减轻化疗反应，延长生存时间。Objective To verify whether LIFEIN improves chemotherapy efficacy and abates chemotherapy reaction of esophageal carcinoma． Methods Seventy－two cases of advanced esophageal carcinoma with metastases were divided into two groups the treatment group and control group． The control group received DF therapy alone.and the treatment group received DF＋LIFDIN therapy． LIFEIN was given for one month at 10mg／d． For DF therapy.DDP 100mg／m2 of body surface on day 1～3 in every chemotherapy cycle and 5－Fu 500mg／m2 of body surface on day 1～5 in every chemotherapy cycle were given． One chemotherapy cycle lasted for 21 days and the therapy lasted for 4～6 cycles． Results 1 The treatment group all underwent therapy as planned.and so did the control group except 4 cases． 2 The efficacy was 62％ in the treatment group and 32％ in the control group χ2＝6．166 P＜0．05． 3 The mean survival time was 12 months in the treatment group and 8 months in the control group． 4 The vomiting reaction during chemotherapy was 70％ in the treatment group and 94％ in the control group P＜0．05． 5 The weight gained 3±1．2Kg in the treatment group and －2±1．7Kg in the control group at the end of the treatment． 6 The levels of CD3.CD4 and CD4／CD8 were significantly increased in the treatment group whereas no change was found in the control group． Conclusion LIFEIN can improve the chemotherapeutic efficacy.prolongs the survival time and enhances the immunity of patients with esophageal carcinoma．

关 键 词：多发性转移食管癌 力尔凡 化疗 DF方案 

分 类 号：R735.1[医药卫生—肿瘤] R730.53[医药卫生—临床医学]